TCRX: TScan Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 238.13
Enterprise Value ($M) 26.42
Book Value ($M) 255.22
Book Value / Share 5.24
Price / Book 0.93
NCAV ($M) 179.88
NCAV / Share 3.69
Price / NCAV 1.32

Profitability (mra)
Return on Invested Capital (ROIC) -0.30
Return on Assets (ROA) -0.36
Return on Equity (ROE) -0.62

Liquidity (mrq)
Quick Ratio 7.77
Current Ratio 7.77

Balance Sheet (mrq) ($M)
Current Assets 299.53
Assets 374.87
Liabilities 119.65
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
9 days ago 13G BlackRock, Inc. 9.50
04-29 13G Cormorant Asset Management, LP 5.15
04-23 13D/A Baker Bros. Advisors Lp 6.10 1.25
02-14 13G/A K2 HealthVentures Equity Trust LLC 9.98 118.50
02-14 13G/A Lynx1 Capital Management LP 7.80 -4.14
02-09 13G/A Gv 2017, L.p. 2.50 0.00
02-08 13G/A Pitango HealthTech Fund I, L.P. 4.30 92.59
02-07 13G/A Adage Capital Partners Gp, L.l.c. 8.96 -2.50

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-04-10 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ T
2024-03-06 10-K Form 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-10-29 29,146 150,619 19.35
2024-10-28 10,593 90,055 11.76
2024-10-25 14,906 172,126 8.66
2024-10-24 13,394 50,766 26.38

(click for more detail)

Similar Companies
SUPN – Supernus Pharmaceuticals, Inc. TARA – Protara Therapeutics, Inc.
TBPH – Theravance Biopharma, Inc. TKNO – Alpha Teknova, Inc.
TLPH – Talphera, Inc.


Financial data and stock pages provided by
Fintel.io